Form 8-K - Current report:
SEC Accession No. 0001213900-24-093768
Filing Date
2024-11-04
Accepted
2024-11-04 08:52:10
Documents
16
Period of Report
2024-11-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0219747-8k_nektar.htm   iXBRL 8-K 28981
2 ASSET PURCHASE AGREEMENT, DATED AS OF NOVEMBER 1, 2024, BETWEEN NEKTAR AND PURCH ea021974701ex1-1_nektar.htm EX-1.1 670698
3 PRESS RELEASE ea021974701ex99-1_nektar.htm EX-99.1 17707
4 GRAPHIC ex99-1_001.jpg GRAPHIC 5814
  Complete submission text file 0001213900-24-093768.txt   1022901

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE nktr-20241101.xsd EX-101.SCH 3009
6 XBRL LABEL FILE nktr-20241101_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE nktr-20241101_pre.xml EX-101.PRE 22355
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0219747-8k_nektar_htm.xml XML 3565
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 241420989
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)